Global Ranibizumab Market Growth (Status and Outlook) 2025-2031

The global Ranibizumab market size is predicted to grow from US$ 2744 million in 2025 to US$ 1432 million in 2031; it is expected to grow at a CAGR of -10.3% from 2025 to 2031.

Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab.

The ranibizumab market is primarily driven by the increasing prevalence of eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and macular edema. As the global population ages and diabetes rates rise, the demand for effective treatments like ranibizumab continues to grow. Ranibizumab, an anti-VEGF (vascular endothelial growth factor) therapy, has proven highly effective in reducing vision loss and improving patient outcomes. Additionally, advancements in drug delivery methods, along with expanding healthcare access in emerging markets, are supporting the growth of the ranibizumab market.

One of the key challenges in the ranibizumab market is the high cost of the drug, which can limit patient access, particularly in developing countries or among uninsured populations. While biosimilar versions are being developed, affordability remains a concern. Additionally, there is growing competition from alternative therapies and biosimilars that offer similar efficacy at a lower price. Patient adherence to treatment regimens, which often require frequent intravitreal injections, can also be a challenge, as some patients may find the process uncomfortable or inconvenient.

Global core ranibizumab manufacturers include Roche and Novartis etc. The Top 2 companies hold a share about 98%. North America is the largest market, with a share about 51%, followed by Europe and Asia Pacific with the share about 28% and 20%.

LPI (LP Information)' newest research report, the “Ranibizumab Industry Forecast” looks at past sales and reviews total world Ranibizumab sales in 2024, providing a comprehensive analysis by region and market sector of projected Ranibizumab sales for 2025 through 2031. With Ranibizumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ranibizumab industry.

This Insight Report provides a comprehensive analysis of the global Ranibizumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Ranibizumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ranibizumab market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ranibizumab and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ranibizumab.

This report presents a comprehensive overview, market shares, and growth opportunities of Ranibizumab market by product type, application, key players and key regions and countries.

Segmentation by Type:
Glass Vial
Prefilled Syringe

Segmentation by Application:
Wet AMD
Complications of Diabetes
RVO
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Coherus
Biogen

Please note: The report will take approximately 2 business days to prepare and deliver.